A PHASE-I TRIAL OF RECOMBINANT HUMAN INTERLEUKIN-6 IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND THROMBOCYTOPENIA
A PHASE-I TRIAL OF RECOMBINANT HUMAN INTERLEUKIN-6 IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND THROMBOCYTOPENIA
复制标题
DOI：
10.1182/blood.v85.11.3066.bloodjournal85113066
复制
发表时间：
1995-06-01
期刊：
影响因子：
20.3
通讯作者：
NIMER, SD
中科院分区：
文献类型：
--
作者：
GORDON, MS;NEMUNAITIS, J;NIMER, SD
为了评价重组人白细胞介素-6（rhIL-6，大肠杆菌，SDZ ILS 969，IL-6）的血液学效应，并确定其毒性特征，我们对22例各种骨髓增生异常综合征（MDS）患者进行了IL-6的I期试验，
To evaluate the hematologic effects of recombinant human interleukin-6 (rhIL-6, Escherichia coli, SDZ ILS 969, IL-6), and determine its toxicity profile, we performed a phase I trial of IL-6 in 22 patients with various myelodysplastic syndromes (MDS), platelet counts